Apitope announces that the first in human clinical trial for the treatment of Graves’ disease has been published as a ‘Success Story’ by the European Commission

Apitope announces that the first in human clinical trial for the treatment of Graves’ disease has been published as a ‘Success Story’ by the European Commission

HASSELT, Belgium, and CHEPSTOW, UK, 13 September 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that the first in human clinical trial for the treatment of Graves’ disease funded by the European Union (DAVIAD) has been published as a “Success Story” on the European Union website. The article entitled ‘ New treatment on the horizon for Graves’ disease’ can be viewed in the following link:

https://ec.europa.eu/research/infocentre/article_en.cfm?artid=50625

Apitope to present at American College of Toxicology and Council

Professor David Wraith Apitope’s co-founder and CSO will present as an invited speaker at the 40th Annual Meeting, 17-20 November, 2019, at the JW Marriott Desert Ridge in Phoenix, Arizona.
Professor Wraith will present during Session 10 entitled ‘Immune Tolerance: State-of-the-Science and Preclinical and Clinical Safety Challenges in Drug Development’:

19 November 2019
Presentation: State-of-Science of Immune Tolerance, and Trending Therapeutic Concepts for New and Differentiated Mechanisms of Action
Time: 09:00am
Presenter: David Wraith